Fair value · Regencell Bioscience Holdings Ltd (RGC) · updated 2026-09-21 · from annual report FY2025
Regencell Bioscience Holdings (RGC): not enough filed data to read assumptions out of the price yet.
These methods need positive earnings and cash flow from the company’s SEC filings. The detailed valuation tools below still work with whatever has been filed.
The filing behind these numbers
Regencell Bioscience Holdings Ltd- Revenue
- $0
- Diluted EPS
- $-0.72
- Free cash flow
- $-3.3M
- operating cash flow − capital expenditure
- Diluted shares
- 494.5M
- weighted average
annual report FY2025 · fiscal year ended 2025-06-30 · filed 2025-10-31 · accession 0001213900-25-104686
Open this filing on sec.govNeed RGC data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.